Genprex, Inc. received a notification from Nasdaq indicating that its common stock is in violation of the $1.00 minimum bid price requirement. Because the company executed a reverse stock split on October 21, 2025, it is ineligible for a 180-day compliance period. The company intends to request a hearing before a Nasdaq Hearings Panel to stay any delisting action. Management is considering further actions, including another reverse stock split, to regain compliance. Genprex, Inc. is a biotechnology company focused on gene therapy.
